SCHEMBL20919403

SCHEMBL20919403

[2H]C([2H])([2H])n1nccc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
LPL P06858 4/20 0.33
LIPG Q9Y5X9 4/20 0.33
FFAR1 O14842 1/20 0.33
P2RX7 Q99572 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL332693 0.87 LPL (0.36) LPLLIPGFFAR1P2RX7
SCHEMBL24664345 0.75 LPL (0.31) LPLLIPG
SCHEMBL24141578 0.74 LPL (0.38) LPLLIPGFFAR1P2RX7
SCHEMBL20820951 0.73 LPL (0.32) LPLLIPGFFAR1
SCHEMBL14742735 0.73 COMT (0.31)
SCHEMBL19207350 0.71 FFAR1 (0.39) LPLLIPGFFAR1P2RX7
SCHEMBL1485368 0.71 ALDH1A1 (0.35) LPLLIPGFFAR1P2RX7
SCHEMBL19796166 0.71 LPL (0.37) LPLLIPGFFAR1P2RX7
SCHEMBL21023551 0.70 FFAR1 (0.35) LPLLIPGFFAR1
SCHEMBL24373133 0.70 LPL (0.35) LPLLIPGFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4733303-A1 MUSCARINIC M4 RECEPTOR AGONIST AND USE THEREOF Haisco Pharmaceutical Group Co., Ltd. (CN) 2026-04-29 EP disclosed
US-12516065-B2 Tertiary alcohols as PI3K-γ inhibitors INCYTE CORPORATION (US) 2026-01-06 US disclosed
US-20250313550-A1 AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2025-10-09 US disclosed
US-12365668-B2 Aminopyrazine diol compounds as PI3K-y inhibitors INCYTE CORPORATION (US) 2025-07-22 US disclosed
WO-2025031468-A1 HETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE 江苏恒瑞医药股份有限公司 2025-02-13 WO disclosed
WO-2024260386-A1 MUSCARINIC M4 RECEPTOR AGONIST AND USE THEREOF 西藏海思科制药有限公司 2024-12-26 WO disclosed
US-20240400541-A1 AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2024-12-05 US disclosed
US-20240228498-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS INCYTE CORPORATION 2024-07-11 US disclosed
US-11926630-B2 Tertiary alcohols as PI3K-γ inhibitors INCYTE CORPORATION (US) 2024-03-12 US disclosed
US-11926616-B2 Aminopyrazine diol compounds as PI3K-γ inhibitors INCYTE CORPORATION (US) 2024-03-12 US disclosed
CN-112074505-A Aminopyrazine diol compounds as PI 3K-gamma inhibitors 因赛特公司 2020-12-11 CN disclosed
US-20200385392-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS INCYTE CORPORATION 2020-12-10 US disclosed
US-20200339542-A1 AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2020-10-29 US disclosed
EP-3697789-A1 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS Incyte Corporation (US) 2020-08-26 EP disclosed
CN-111542526-A Condensed imidazole derivatives substituted by tertiary hydroxyl group as PI 3K-gamma inhibitor 因赛特公司 2020-08-14 CN disclosed
US-10738057-B2 Tertiary alcohols as PI3K-γ inhibitors INCYTE CORPORATION (US) 2020-08-11 US disclosed
US-10669262-B2 Aminopyrazine diol compounds as PI3K-γ inhibitors INCYTE CORPORATION (US) 2020-06-02 US disclosed
US-20190276435-A1 AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2019-09-12 US disclosed
US-20190152975-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS INCYTE CORPORATION 2019-05-23 US disclosed
WO-2019079469-A1 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION (US) 2019-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10669262-B2 Aminopyrazine diol compounds as PI3K-γ inhibitors PIK3CD, PIK3R5, PIK3CG LPL 3966/4885LIPG 1264/4885FFAR1 2031/4885
US-20240228498-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS PIK3R5, PIK3R1, PIK3CD LPL 873/4885LIPG 203/4885FFAR1 741/4885
US-20240400541-A1 AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS PIK3CD, PIK3R5, PIK3CG LPL 4287/4885LIPG 1769/4885FFAR1 2381/4885
US-20190276435-A1 AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS PIK3CD, PIK3R5, PIK3CG LPL 4287/4885LIPG 1769/4885FFAR1 2381/4885
US-20190152975-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS PIK3R5, PIK3R1, PIK3CD LPL 873/4885LIPG 203/4885FFAR1 741/4885
US-11926616-B2 Aminopyrazine diol compounds as PI3K-γ inhibitors PIK3CD, PIK3R5, PIK3CG LPL 3966/4885LIPG 1264/4885FFAR1 2031/4885
US-10738057-B2 Tertiary alcohols as PI3K-γ inhibitors PIK3R5, PIK3CG, PIK3CD LPL 642/4885LIPG 112/4885FFAR1 663/4885
US-12365668-B2 Aminopyrazine diol compounds as PI3K-y inhibitors PIK3CD, PIK3R5, PIK3CG LPL 4287/4885LIPG 1769/4885FFAR1 2381/4885
US-20200385392-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS PIK3R5, PIK3R1, PIK3CD LPL 873/4885LIPG 203/4885FFAR1 741/4885
US-20250313550-A1 AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS PIK3CD, PIK3R5, PIK3CG LPL 4287/4885LIPG 1769/4885FFAR1 2381/4885
US-20200339542-A1 AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS PIK3CD, PIK3R5, PIK3CG LPL 4287/4885LIPG 1769/4885FFAR1 2381/4885
US-11926630-B2 Tertiary alcohols as PI3K-γ inhibitors PIK3R5, PIK3CG, PIK3CD LPL 642/4885LIPG 112/4885FFAR1 663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.